CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for KAKEN PHARMACEUTICAL CO., LTD. is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

KAKEN PHARMACEUTICAL CO., LTD.
20F, Bunkyo Green Court Center Office
2-28-8, Honkomagome
Phone: +81 359775001p:+81 359775001 BUNKYO-KU, TKY  113-8650  Japan Ticker: 45214521

Business Summary
KAKEN PHARMACEUTICAL CO., LTD. is a Japan-based company engaged in the production and sale of pharmaceutical products. The Company operates in two business segments. The Pharmaceutical segment involves in the manufacture and sale of pharmaceuticals, medical devices and agricultural drugs. The Real Estate segment is engaged in the leasing of real estate.
(Source: F-4)

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
9/30/20243/31/2024Yes----

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
President, Representative Director HiroyukiHoriuchi 60 6/1/2021 6/1/2016
Executive Officer, Chief Director of Sales TomoyukiKoseki 7/1/2023 7/1/2023
Executive Officer, Deputy Chief Director of Research and Development, Manager of New Drug Discovery TatsuhiroHarada 7/1/2023 7/1/2023
8 additional Officers and Directors records available in full report.

Business Names
Business Name
4521
Kaken Pharmaceutical Co., Ltd.

General Information
Number of Employees: 1,135 (As of 3/31/2024)
Outstanding Shares: 37,874,084 (As of 9/30/2024)
Shareholders: 12,875
Stock Exchange: TYO
Fax Number: +81 359775131


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Tuesday, December 3, 2024